Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Tilarginine

Small molecule · Inhibitor of nitric oxide synthase · developed by Heron Therapeutics

Phase 4 Most advanced trial (none active)
HRTX Developer
1 Registered trials

What is Tilarginine?

Tilarginine is a pan-nitric oxide synthase (NOS) inhibitor that binds and inhibits NOS, a free radical signaling molecule that promotes angiogenesis, metastasis and immunosuppression in the tumor microenvironment. Reducing NOS activity is intended to relieve tumor immunosuppression and enhance tumor antigen-specific immune responses.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
MMA regimen
Drug type
Small molecule
Targets
nitric oxide synthase
Mechanism
Inhibitor of nitric oxide synthase
Pathways
angiogenesis, tumor immunosuppression, metastasis
Therapy area
Oncology
Developer
Heron Therapeutics (HRTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 4
UNII
27JT06E6GR

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06109428 Phase 4 Postoperative Pain Completed HRTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Analgesia

More from Heron Therapeutics

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the HRTX page.

Follow HRTX, the company behind Tilarginine

See HRTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

HRTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.